ABX464: Clinical Trials

19 trials of ABX464, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 2 active not recruiting, 1 terminated, 1 withdrawn. 12 Phase 2, 5 Phase 1, 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 212Completed 9, Active not recruiting 1, Terminated 1, Withdrawn 1
Phase 15Completed 5
Phase 35Completed 2, Active not recruiting 1, Terminated 1, Withdrawn 1

Follow ABX464: new trials by email Literature Review of ABX464 trials Research Report on ABX464

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
ABX464, Placebo - Ulcerative Colitis
Phase 3CompletedAbivax S.A.6362023-01-252026-09-10
ABTECT - Maintenance
ABX464, Placebo - Ulcerative Colitis
Phase 3Active not recruitingAbivax S.A.11162023-01-162026-07-07
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
ABX464, Placebo - Ulcerative Colitis
Phase 3CompletedAbivax S.A.6392022-11-162026-09-10
Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients
ABX464, Placebo - Crohn Disease
Phase 2 / Phase 3WithdrawnAbivax S.A.2022-09-192024-07-31
Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
ABX464 - Ulcerative Colitis
Phase 2Active not recruitingAbivax S.A.2032021-12-032026-04-27
Safety and Pharmacokinetics Study in Healthy Japanese Volunteers
ABX464, Placebo - Healthy Volunteers
Phase 1CompletedAbivax S.A.482021-09-272023-01-26
Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464
Caffeine, ABX464, Fluvoxamine - Healthy
Phase 1CompletedAbivax S.A.592020-12-172026-11-09
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
ABX464, Placebo - COVID-19
Phase 2 / Phase 3TerminatedAbivax S.A.5092020-07-012025-11-26
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
ABX464 - Ulcerative Colitis
Phase 2CompletedAbivax S.A.2172020-01-132026-05-06
Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis
ABX464 - Rheumatoid Arthritis
Phase 2CompletedAbivax S.A.402019-10-252025-11-17
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
ABX464 100 mg, ABX464 50 mg, ABX464 25 mg - Ulcerative Colitis
Phase 2CompletedAbivax S.A.3552019-08-132025-11-28
Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
ABX464 50mg, Matching Placebo, ABX464 100mg - Rheumatoid Arthritis
Phase 2CompletedAbivax S.A.602019-07-042023-02-15
Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis
ABX464 - Ulcerative Colitis
Phase 2CompletedAbivax S.A.222018-01-202025-05-29
ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
ABX464, Placebo oral capsule - Ulcerative Colitis
Phase 2CompletedAbivax S.A.322017-11-162024-06-03
A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults
ABX464 150mg, ABX464 50mg - HIV Infections, Health Volunteers
Phase 1 / Phase 2CompletedAbivax S.A.362017-03-272023-03-31
ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment
ABX464, Placebo - HIV Infection
Phase 2CompletedAbivax S.A.302016-05-012024-09-19
Safety, PK and PD Study of ABX464 in Untreated HIV Patients
ABX464, Placebo - Human Immunodeficiency Virus Infections
Phase 2CompletedAbivax S.A.702015-01-012016-05-30
Food Effect on Pharmacokinetic Parameters of ABX464
ABX464 Single dose, ABX464 Repeated dose - Healthy Volunteers
Phase 1CompletedAbivax S.A.482014-09-012016-04-08
ABX464 First in Man Study
ABX464 - Healthy Volunteers
Phase 1CompletedAbivax S.A.242014-03-012024-05-17

Conditions studied

Colitis, Ulcerative (8)  ·  Arthritis, Rheumatoid (2)  ·  HIV Infections (2)  ·  COVID-19 (1)  ·  Crohn Disease (1)

Sponsors

Abivax S.A. (19)

Countries

Belgium (13)  ·  France (12)  ·  Spain (10)  ·  Hungary (9)  ·  Poland (9)  ·  Czechia (8)  ·  Germany (8)  ·  Italy (7)  ·  United Kingdom (7)  ·  Austria (6)  ·  Canada (6)  ·  Serbia (5)  ·  Slovakia (5)  ·  Ukraine (5)  ·  United States (4)

Top investigators

Bruce Sands, MD, PhD (3)  ·  Severine Vermeire, MD, PhD (3)  ·  Bram Verstockt, MD (1)  ·  Laurence Desroys du Roure, PharmD (1)  ·  Paul Gineste (1)

Results publications

PMID 27799203, PMID 27999038, PMID 28507108, PMID 30800421, PMID 34436569, PMID 35641124, PMID 36075249, PMID 40417999